Gene Therapy covers both the research and clinical applications of novel therapeutic techniques based on a genetic component. Over the last few decades, significant advances in technologies ranging from identifying novel genetic targets that cause disease through to clinical studies, which show therapeutic benefit, have elevated this multidisciplinary field to the forefront of modern medicine.

Gene Therapy covers all aspects of gene therapy as applied to human disease, including:

    preliminary studies which reveal novel genetic targets or strategies that improve a disease phenotype (Note: studies showing the mechanistic role of genetic elements alone, will be considered if significant therapeutic benefit or novelty is shown)
    the development of novel techniques for gene therapy research and improvements on established tools
    preclinical animal model systems and validation studies
    gene-based vaccine development and applications
    genetically engineered cellular models that can advance the validation of novel therapeutic targets, and drug discovery especially those using high-throughput applications and 3D modelling
    cell-based therapies including all aspects of stem cells and genetically modified cellular approaches (especially CRISPR and other gene editing strategies), including biobanking studies
    clinical trial reports which have significant impact for the field
    novel genetic biomarkers of disease susceptibility or disease progression with extensive scientific validation
    Industry sector pipeline profiles or commercial implications of gene therapies
    Regulatory landscapes and legislative issues pertaining to different global regions

Article
Review Article
News
Brief Communication
Editorial
Comment

Editor-in-Chief
Rafael J. Yáñez–Muñoz
Rafael J. Yáñez-Muñoz is Professor of Advanced Therapy and Director of the Centre of Gene and Cell Therapy (CGCT) at the School of Biological Sciences, Royal Holloway, University of London, UK. Rafael received his BSc and PhD in Biochemistry and Molecular Biology from the Autonomous University of Madrid, Spain. He leads the Advanced Gene and Cell Therapy lab (AGCTlab) at Royal Holloway's CGCT. Rafael is a member of the Board of the British Society for Gene and Cell Therapy, and currently its Treasurer. He believes it is very important to engage with the wider society, is the Chair of trustees of the Genetic Alliance UK and organises a yearly outreach event on Rare Disease Day. He is delighted to have been appointed as Editor-in-Chief of Gene Therapy and set out his vision for the journal in an editorial published in September 2017, in a special issue devoted to Spinraza and more generally to the importance of involving all stakeholders for the successful development and marketing of advanced therapies.

Associate Editors
 Qiurong Ding, Asia
Qiurong Ding is Principle Investigator at the Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS). Qiurong received her BSc in Biology from Nanjing University, China and her PhD in Biochemistry and Molecular Biology from SIBS, CAS, China. She then did her postdoctoral research in Harvard Stem Cell Institute and Harvard Department of Stem Cell and Regenerative Biology, USA. She is a recipient of the National Youth 1000 Talents Program Award in China. Her research interest is to understand the genetic underpinnings of human cardio-metabolic diseases and develop novel therapeutics.
Marguerite Evans-Galea, Australasia
Dr Evans-Galea is a scientist, leader, researcher, speaker, author and entrepreneur. She is the inaugural Executive Director of the Industry Mentoring Network in STEM (IMNIS) with the Australian Academy of Technology and Engineering (ATSE). Dr Evans-Galea is also an honorary investigator at the Murdoch Childrens Research Institute and The University of Melbourne. With a PhD in molecular biology and over 15 years experience leading translational medical research programs in cell and gene therapy at world-leading organisations in the United States and Australia, Dr Evans-Galea’s research and leadership has been internationally recognised with numerous awards. She has served as an Executive member with the Australasian Gene and Cell Therapy Society and with the Immune Responses Committee at the American Society of Gene and Cell Therapy. Committed to empowering early-mid career researchers (EMCR) and women in science, Dr Evans-Galea regularly mentors students, fellows and faculty, was the founding chair of the EMCR Forum with the Australian Academy of Science, co-founder of Women in STEMM Australia, and serves on the Science in Australia Gender Equity Expert Advisory Group. She is also an active contributor to the APEC Women in STEMM program. Dr Evans-Galea communicates regularly on science-related topics via social and mainstream media, has received an Australian Leadership Award, and is an Ambassador for the Victorian Honour Roll of Women and the Scienceworks museum. Dr Evans-Galea is passionate about fostering stronger international ties between experts in gene therapy and stem cell research.
Twitter @MVEG001
LinkedIn https://www.linkedin.com/in/margueriteevansgalea/  
Theodore Friedmann, North America
Theodore Friedmann, M.D. is internationally recognized for pioneering the birth and development of the concepts and key tools of human gene therapy. He is a Professor of Pediatrics and Muriel Whitehill Chair of Biomedical Ethics at the School of Medicine of the University of California San Diego (UCSD) and is a member of the UCSD Institute for Genomic Medicine. Following his A.B and M.D degrees at the University of Pennsylvania, Dr. Friedmann received his clinical training in pediatrics at the Children's Hospital and the Massachusetts General Hospital of Harvard University in Boston and did postdoctoral fellowships at the University of Cambridge, the National Institutes of Health, and the Salk Institute. In 1972, along with his colleague Richard Roblin, Ph.D., Dr. Friedmann published what is considered by many to be the first description of the need for and directions toward gene therapy for human disease. Since the publication of that article, Dr. Friedmann has continued to be a leader in human gene therapy as Director of the Gene Therapy Program at UCSD since 1993. His laboratory has made many important scientific and policy advances toward the goal of safe and effective gene therapy. Dr. Friedmann has been a national and international leader in the ethical and public policy aspects of human genetics and gene therapy, having served as a member of many national and international organizations including chairmanship of the U.S. National Institutes of Health DNA Advisory Committee, (RAC) and of the American Association for the Advancement of Science advisory committee on human germ line genetic modification. He served as president of the American Society for Gene and Cell Therapy, founding editor of Advances in Genetics and is current chairman of the genetics expert panel for the World Anti-Doping Agency. He has been recognized for his foundational work in human genetics, childhood neurodevelopment disease and gene therapy, including the Cross of Honor for Science and Art from the Republic of Austria, the Newton Abraham Chair at the University of Oxford and the 2015 Japan Prize in Medical Sciences and Medicinal Science.
Patrick Harrison, Europe
Patrick T Harrison is Senior Lecturer in Molecular Physiology in the Department of Physiology, BioSciences Institute, University College Cork (UCC), Ireland. He received his PhD in Virology from the University of Glasgow, UK, and BSc in Biochemistry from the University of Liverpool, UK. Patrick heads a Gene Editing Lab at UCC with a focus on correcting disease-causing mutations in Cystic Fibrosis and Cystinosis, and editing iPS cells to model skin disorders. He is a member of both the Physiological Society and the British Society for Gene and Cell Therapy which reflects his dual interest in using molecular techniques to better understand physiological processes in the context of developing gene-based approaches to treat disease. He is delighted to join Rafael and the rest of the Gene Therapy team as Associate Editor (Europe). 
Janine Scholefield, Africa
After completing her PhD in Human Genetics at the University of Cape Town (UCT), Janine Scholefield spent three years as a Nuffield Medical Fellow at the University of Oxford. Since returning to South Africa she has specialised in cellular modelling of disease by being the first to establish induced pluripotent stem cell research in the country. Her research interest is in developing physiologically relevant cellular models of disease using advanced technologies, including super-resolution microscopy, stem cells and genome engineering, especially within the unique context of the diverse sub-Saharan African genetic background. She is currently a Senior Researcher at the Council for Scientific and Industrial Research and holds an Honorary lectureship position in the Department of Human Biology at UCT. Janine is particularly engaged in promoting African research and its scientists by building collaborative networks from within the continent across the globe. 
Ursula da Silveira Matte, South America
Ursula Matte graduated in Biological Sciences at the Universidade Federal de Rio Grande do Sul (UFRGS) and obtained her Ph.D. in Genetics and Molecular Biology at the same university. Her post-doctoral training was at the Cincinnati Children's Hospital Medical Center (USA). She is currently coordinator of the Research Center at Hospital de Clinicas de Porto Alegre (HCPA), and professor of Genetics at UFRGS. Research topics include gene therapy for mucopolysaccharidoses, bioethics and genetics, and molecular diagnosis of genetic diseases. She was elected affiliated member of the Brazilian Academy of Sciences in 2008.
Social Media Editor
Versha Prakash, UK
Versha Prakash is a post-doctoral research associate in the Advanced Gene and Cell Therapy lab (www.AGCTlab.org) under the mentorship of Prof Rafael Yáñez. She is currently leading a project on developing CRISPR/Cas technology as a therapy for the genetic condition Ataxia telangiectasia (A-T). She is being funded by the patient charity Action for A-T. Versha received her BSc in Biochemistry with science communication and a PhD in gene therapy from Royal Holloway University of London, UK.